4.6 Article

Thromboprophylaxis in the intensive care unit: Focus on medical-surgical patients

期刊

CRITICAL CARE MEDICINE
卷 38, 期 2, 页码 S76-S82

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0b013e3181c9e344

关键词

venous thromboembolism; prevention; critical illness

资金

  1. Heart and Stroke Founds of Canada
  2. Bayer Healthcare
  3. Boehringer Ingelheim
  4. Artisan Pharma
  5. Leo Laboratories
  6. Sanofi Aventis
  7. Pfizer

向作者/读者索取更多资源

Critically ill patients in the medical-surgical intensive care unit are at high risk for deep venous thrombosis and pulmonary embolism, which comprise venous thromboembolism. Herein, we describe the prevalence, incidence, risk factors, clinical consequences, prophylaxis against venous thromboembolism in critically ill patients, and compliance with thromboprophylaxis. We focus primarily on medical-surgical intensive care unit patients, who represent the largest subgroup of critically ill patients. Despite the large and growing number of critically ill patents in our aging society, their high risk for venous thromboembolism, and the morbidity and mortality associated with this complication of critical illness, relatively few rigorous studies are available. Large, well-designed, randomized trials of thromboprophylaxis, powered to detect differences in patient-important outcomes, are required to advance our understanding and care of these vulnerable patients. Furthermore, because thromboprophylaxis is a common error of omission in hospitalized patients, redoubled efforts are needed to ensure that it is used in practice. (Crit Care Med 2010; 38[Suppl.]:S76-S82)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据